Solcitinib

Drug Profile

Solcitinib

Alternative Names: G154578; GLPG-0778; GSK-2586184; GSK2586184A

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Galapagos NV
  • Developer GlaxoSmithKline
  • Class Amides; Azetidines; Cyclopropanes; Pyridines; Small molecules; Triazoles
  • Mechanism of Action Immunosuppressants; Janus kinase 1 inhibitors; Signal transduction pathway inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase Unknown Unspecified
  • Discontinued Plaque psoriasis; Systemic lupus erythematosus; Ulcerative colitis

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 06 Nov 2014 Efficacy and adverse events data from a phase IIa trial in Plaque psoriasis released by Galapagos
  • 26 Aug 2014 Discontinued - Phase-I for Ulcerative colitis in Netherlands (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top